1. Home
  2. VICR vs IMVT Comparison

VICR vs IMVT Comparison

Compare VICR & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vicor Corporation

VICR

Vicor Corporation

HOLD

Current Price

$200.53

Market Cap

7.6B

Sector

Technology

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.80

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VICR
IMVT
Founded
1981
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
5.3B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
VICR
IMVT
Price
$200.53
$26.80
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$132.50
$30.78
AVG Volume (30 Days)
670.1K
1.2M
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
1764.29
N/A
EPS
2.61
N/A
Revenue
$452,701,000.00
N/A
Revenue This Year
$17.33
N/A
Revenue Next Year
$14.44
N/A
P/E Ratio
$130.14
N/A
Revenue Growth
26.08
N/A
52 Week Low
$38.93
$12.72
52 Week High
$209.00
$29.25

Technical Indicators

Market Signals
Indicator
VICR
IMVT
Relative Strength Index (RSI) 67.41 51.75
Support Level $44.52 $24.63
Resistance Level N/A $27.71
Average True Range (ATR) 15.65 1.10
MACD 3.42 0.06
Stochastic Oscillator 89.22 41.11

Price Performance

Historical Comparison
VICR
IMVT

About VICR Vicor Corporation

Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: